# Fennec Pharmaceuticals Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Fennec Pharmaceuticals Inc).

## Overview

Fennec Pharmaceuticals is a U.S.-based commercial-stage biopharmaceutical company focused on PEDMARK® (sodium thiosulfate injection), a therapy used to reduce cisplatin-induced hearing loss in pediatric cancer patients. The company also monetizes its asset through licensing arrangements, including commercialization rights outside the U.S. for PEDMARQSI®/PEDMARK®.

## Products & services

• PEDMARK® (sodium thiosulfate injection)
• PEDMARQSI® European brand of PEDMARK®
• License agreements with pharmaceutical companies
• Commercialization rights for ex-U.S. markets
• Royalty and milestone-based collaboration revenue

- **Commercial product sales** (55%) — Sales of PEDMARK® in the U.S. and related branded product commercialization.
- **International licensing** (35%) — Out-licensing of PEDMARQSI® rights to partners for Europe, Australia and New Zealand.
- **Milestones and upfront fees** (10%) — Non-refundable upfront payments and milestone receipts under collaboration agreements.

- PEDMARK® (sodium thiosulfate injection)
- PEDMARQSI® European brand of PEDMARK®
- License agreements with pharmaceutical companies
- Commercialization rights for ex-U.S. markets
- Royalty and milestone-based collaboration revenue

## Customers

Fennec sells primarily into the life sciences and pharmaceutical ecosystem rather than to mass-market consumers. Its direct customers include hospitals, oncology treatment centers, and pharmaceutical partners that commercialize or license PEDMARK/PEDMARQSI in specific territories.

- **Pediatric oncology providers** (primary) — Hospitals and cancer centers buy PEDMARK for children receiving cisplatin to reduce hearing-loss risk.
- **Pharmaceutical commercialization partners** (primary) — Partners license rights to market PEDMARQSI/PEDMARK in defined territories and pay milestones or royalties.
- **Specialty pharmacy and distribution channels** (secondary) — Channel partners distribute the product to treatment sites and support access and reimbursement.
- **International oncology markets** (secondary) — Ex-U.S. markets buy through local commercialization partners as approvals and launches expand.

- Pediatric oncology treatment centers using PEDMARK with cisplatin
- Hospitals and infusion sites treating localized solid tumors
- Pharmaceutical partners licensing regional commercialization rights
- European specialty pharma partner Norgine for ex-U.S. launch
- Customers buy to reduce cisplatin-related ototoxicity risk

## Geography

The company is headquartered in the United States, where PEDMARK was first approved and where commercial activity is centered. Outside the U.S., Fennec has expanded through licensing, with PEDMARQSI approved in the EU and U.K. and launched in Germany and the U.K. through Norgine. This makes the business dependent on regulatory approvals and partner execution in Europe and other ex-U.S. markets.

- United States is the core commercial and corporate base
- EU and U.K. are key approved ex-U.S. markets for PEDMARQSI
- Germany and the U.K. are early launch markets via Norgine
- Australia and New Zealand are covered by the Norgine license
- Geography matters because approvals and launches drive adoption

## Strategy

Fennec is pursuing commercialization of its single approved product while broadening access through regional licensing partnerships. Management is also actively evaluating strategic alternatives and collaborations to secure funding, extend runway, and support future development and commercialization efforts.

- **Grow PEDMARK adoption in the U.S.** (short-term) — The company depends heavily on one commercial asset, so uptake drives revenue and operating leverage.
- **Scale ex-U.S. commercialization through partners** (medium-term) — Licensing reduces direct operating burden while expanding market reach and potential royalty streams.
- **Secure additional capital and strategic options** (short-term) — Working capital needs remain uncertain and the company references further capital requirements.

- Expand PEDMARK/PEDMARQSI adoption in approved markets
- Use licensing partners to reach Europe and other ex-U.S. regions
- Pursue collaborations that bring upfront, milestone, or royalty income
- Preserve capital while funding commercialization and development
- Evaluate strategic alternatives to strengthen long-term viability

## Risks

Fennec is highly concentrated in a single product and therefore exposed to adoption, reimbursement, and regulatory execution risk. Its partner-led international expansion reduces direct investment needs but increases dependence on third parties, while ongoing capital needs and clinical/regulatory uncertainty remain material for a small biopharma company.

- **Single-product concentration** [high] — Revenue and strategic value are tied primarily to PEDMARK/PEDMARQSI, so any setback would materially affect the business.
- **Partner dependence** [high] — International growth relies on Norgine and other collaborators to launch, market, and distribute the product.
- **Financing and liquidity risk** [high] — Management states future capital requirements are uncertain and may depend on collaboration proceeds or financing.
- **Regulatory and market access risk** [medium] — Approvals, label scope, and reimbursement determine whether hospitals can adopt the therapy at scale.

- Single-product concentration creates outsized dependence on PEDMARK
- Partner execution risk in Europe and other ex-U.S. markets
- Capital needs may require dilutive financing or strategic deals
- Regulatory and reimbursement changes can slow adoption
- Clinical, safety, and commercialization setbacks could limit growth

## Accounting

Revenue recognition is judgmental because Fennec records license revenue under ASC 606 using upfront fees, milestones, and royalties that depend on contract terms and future events. The company also carries expected credit loss estimates on receivables and uses performance-based equity awards tied to revenue milestones, which can affect both reported revenue timing and compensation expense.

- **ASC 606 license revenue** — Can shift revenue between periods and affect comparability.
- **Expected credit losses** — Affects bad debt expense and net receivables.
- **Performance-based equity awards** — Can increase compensation expense if milestones are expected to be achieved.
- **Fair value of cash equivalents** — Minor but relevant for treasury and liquidity analysis.

- License revenue depends on upfront fees, milestones, and royalties
- ASC 606 judgments affect timing of revenue recognition
- Expected credit loss estimates affect trade receivables
- PSU expense depends on probability of revenue milestones
- Cash and money market investments are marked to fair value

---

*Last updated: 2026-09-24T10:46:58.155164+00:00*